Voloridge Investment Management LLC Buys 515,836 Shares of Pfizer Inc. (NYSE:PFE)

Voloridge Investment Management LLC raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 27.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,402,685 shares of the biopharmaceutical company's stock after acquiring an additional 515,836 shares during the quarter. Voloridge Investment Management LLC's holdings in Pfizer were worth $63,743,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Tallon Kerry Patrick acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $509,000. Ameritas Advisory Services LLC increased its stake in shares of Pfizer by 3.6% in the fourth quarter. Ameritas Advisory Services LLC now owns 75,983 shares of the biopharmaceutical company's stock valued at $2,016,000 after buying an additional 2,633 shares during the period. Diversify Wealth Management LLC increased its stake in shares of Pfizer by 13.9% in the fourth quarter. Diversify Wealth Management LLC now owns 10,750 shares of the biopharmaceutical company's stock valued at $287,000 after buying an additional 1,308 shares during the period. Amplius Wealth Advisors LLC increased its stake in shares of Pfizer by 80.7% in the fourth quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company's stock valued at $1,242,000 after buying an additional 20,911 shares during the period. Finally, Bonness Enterprises Inc. increased its stake in shares of Pfizer by 3.4% in the fourth quarter. Bonness Enterprises Inc. now owns 161,508 shares of the biopharmaceutical company's stock valued at $4,285,000 after buying an additional 5,300 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Pfizer stock opened at $23.51 on Wednesday. The stock has a market capitalization of $133.66 billion, a price-to-earnings ratio of 16.67, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The stock's 50 day moving average price is $23.56 and its two-hundred day moving average price is $25.27. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.82 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.32%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Ratings Changes

Several research firms have recently issued reports on PFE. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.